The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.

Marina VilasecaHéctor García-CalderóErica LafozOihane García-IrigoyenMatías A AvilaJoan Carles ReverterJaume BoschVirginia Hernández-GeaJordi Gracia-SanchoJoan Carles García-Pagán

Published in: Hepatology (Baltimore, Md.) (2017)

RVXB decreases PP in two rat models of cirrhosis. This effect is mostly associated with decreased IHVR, enhanced NO bioavailability, HSC deactivation, and reduced intrahepatic microthrombosis. Our findings suggest that RVXB deserves further evaluation as a potential treatment for cirrhotic PH. (Hepatology 2017;65:2031-2044).

Keyphrases

venous thromboembolism
atrial fibrillation
induced apoptosis
blood pressure
cell cycle arrest
oxidative stress
pulmonary embolism
cell proliferation
climate change
replacement therapy